Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Liver Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
13 drugs · 38 active trials
14 drugs · 333 active trials
Outside the funnel: Phase not stated 3. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 19 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Olaparib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Jul 31, 2017 |
| Sacituzumab Govitecan | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Dec 17, 2012 |
| Samotolisib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Jul 31, 2017 |
| Selumetinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | 2007-11 |
| Trastuzumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Vemurafenib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Jul 31, 2017 |
| Acalabrutinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Dec 13, 2019 |
| Adavosertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Afatinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Capivasertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Cemiplimab | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Jul 23, 2019 |
| Crizotinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Dabrafenib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Denosumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | May 1, 2026 |
| Dostarlimab | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Mar 6, 2025 |
| Enfortumab Vedotin | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Apr 1, 2025 |
| Eribulin | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | May 30, 2023 |
| Fexagratinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Immunomodulatory Oligonucleotide | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | 2024-10 |
| Ipatasertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Osimertinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| PD-L1 Inhibitor | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jan 1, 2025 |
| Pertuzumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Platinum Doublet | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Jul 23, 2019 |
| Talazoparib | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jun 9, 2021 |
| Taselisib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Trastuzumab Emtansine | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Vismodegib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Erlotinib Hydrochloride | Phase 2 | Phase 2 | 0 | 0 | 0 | 9 | 0 | — | — | 2001-12 |
| Melphalan | Phase 2 | Phase 2 | 0 | 0 | 0 | 9 | 0 | — | — | 1998-11 |
| Filgrastim | Phase 2 | Phase 2 | 0 | 0 | 0 | 8 | 0 | — | — | 1992-10 |
| Axitinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 7 | 0 | — | — | Dec 6, 2010 |
| Busulfan | Phase 2 | Phase 2 | 0 | 0 | 0 | 7 | 0 | — | — | 1988-03 |
| Cetuximab | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | 2005-01 |
| Tegafur | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | 2006-07 |
| Thiotepa | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | 1992-10 |
| Aldesleukin | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 1997-10 |
| Cixutumumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2008-03 |
| Akt Inhibitor MK2206 | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2010-12 |
| Alisertib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2011-02 |
| Avelumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | Sep 8, 2017 |
| Cediranib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2005-12 |
| Nintedanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2009-10 |
| Panobinostat | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2009-03 |
| Romidepsin | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | Oct 29, 2012 |
| Tivozanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2013-03 |
| Veliparib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2007-08 |
| Alemtuzumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2001-11 |
| Alvocidib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2001-04 |
| Capmatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Jun 15, 2016 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.